Benefit from the use of C5 blockade has been demonstrated in some forms of secondary HUS, suggesting that dysregulation of the alternative complement pathway may be involved in its pathogenesis [1,2,3]. The gene discussed is C5; the disease is hemolytic-uremic syndrome.